Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAINRIPAC: Rituximab vs azathioprine for remission maintenance in primary angiitis of the central nervous system
2026-525394-39-00Phase 2Authorised
- Sponsor
- GHU Paris psychiatrie & neurosciences
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in primary angiitis of the central nervous system (PACNS) (2 arms), sponsored by GHU Paris psychiatrie & neurosciences. Primary endpoint: Time to relapse. Planned start Aug 2026; status: authorised.
02
Drugs
rituximab
03
Conditions
primary angiitis of the central nervous system (PACNS)
Beyond the preview
Go deeper on 2026-525394-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525394-39-00.